Vectibix Solution For Injection 20Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Vectibix: Solution for injection (20mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PANITUMUMAB (pan i TOOM ue mab) is a monoclonal antibody. It is used to treat colorectal cancer.

In-Depth Information
Select a Medication

Vectibix 400mg/20ml Solution for Injection

NDC: 555130956
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Colorectal Cancer

Storage Information
Store in original carton in refrigerator (35 to 46 degrees F) until time of use
Discard product if it contains particulate matter, is cloudy, or discolored
Do not freeze
Discard unused portion. Do not store for later use.
Protect from direct sunlight
Diluted product should be used within 6 hours if stored at room temperature or within 24 hours if stored at 36 to 46 degrees F
Vectibix 400mg/20ml Solution for Injection

Reported Side Effects for Vectibix 400mg/20ml Solution for Injection

Antibody Formation Incidence:
<3.2%*
Severity: MODERATE
Onset: DELAYED
Infusion-related Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Blistery Rash Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Conjunctivitis Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Dry Skin Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Stevens-Johnson Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Pulmonary Fibrosis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Itching Incidence:
<3.0%*
Severity: SEVERE
Onset: RAPID
Hand And Foot Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Skin Necrosis Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Exfoliative Dermatitis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Skin Ulcer Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
<5.0%*
Severity: SEVERE
Onset: EARLY
Lyell'S Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Dehydration Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Weight Loss Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Appetite Incidence:
<4.0%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Skin Rash Incidence:
1.0-17.0%*
Severity: SEVERE
Onset: EARLY
Eye Irritation Incidence:
1.0%*
Severity: MILD
Onset: RAPID
Acne Incidence:
1.0-3.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot In Lung Incidence:
1.3%*
Severity: SEVERE
Onset: DELAYED
Skin Redness Incidence:
2.0-6.0%*
Severity: SEVERE
Onset: EARLY
Secretion Of Tears Incidence:
2.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
2.0-18.0%*
Severity: SEVERE
Onset: EARLY
Vomiting Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Red Eyes Incidence:
3.0%*
Severity: MODERATE
Onset: EARLY
Chills Incidence:
3.1%*
Severity: MILD
Onset: RAPID
Infection Incidence:
3.7%*
Severity: MILD
Onset: DELAYED
Nose Bleed Incidence:
3.9-14.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
4.0%*
Severity: SEVERE
Onset: EARLY
Dry Mouth Incidence:
4.8%*
Severity: MILD
Onset: EARLY
Blood Clot Incidence:
5.3%*
Severity: SEVERE
Onset: DELAYED
Low Calcium Levels Incidence:
5.6%*
Severity: MODERATE
Onset: DELAYED
Ambras Syndrome Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Low Magnesium Levels Incidence:
7.0%*
Severity: SEVERE
Onset: DELAYED
Drug-Induced Acne Incidence:
7.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Low Potassium Levels Incidence:
10.0%*
Severity: SEVERE
Onset: DELAYED
Hair Loss Incidence:
15.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
16.6%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Vectibix

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5